Finoriq research workspace
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) SEC Filings & Filing Highlights
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in. Review ARWR SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
- Company
- ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Ticker
- ARWR
- Market Cap
- $10.1B
- Latest Price
- $71.69
- Industry
- Biotech & Pharma
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
| Event | Form | Date |
|---|---|---|
| (d) Appointment of Dr. Matt Cohen as a Director On June 12, 2026, the Board of Directors of Arr...(d) Appointment of Dr. Matt Cohen as a Director On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”)... | 8-K5.02 | 2026-06-16 |
| Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter ResultsArrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results | 8-K2.02 | 2026-05-07 |
| The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. a...The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. (the “Company”) at the 2026 Annual Meeting of... | 8-K5.07 | 2026-03-20 |
| February 5, 2026Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results | 8-K2.02 | 2026-02-05 |
| Indenture and NotesOn January 12, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) issued $700,000,000 aggregate principal amount of its 0.00% Convertibl... | 8-K1.01 | 2026-01-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.